Northern Trust Corp raised its stake in Cascadian Therapeutics, Inc. (NASDAQ:CASC) by 415.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 382,469 shares of the biopharmaceutical company’s stock after purchasing an additional 308,270 shares during the period. Northern Trust Corp owned 0.78% of Cascadian Therapeutics worth $1,420,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in CASC. State of Wisconsin Investment Board bought a new stake in shares of Cascadian Therapeutics during the 2nd quarter valued at about $104,000. New York State Common Retirement Fund acquired a new position in Cascadian Therapeutics during the 2nd quarter valued at about $136,000. BB&T Securities LLC acquired a new position in Cascadian Therapeutics during the 2nd quarter valued at about $143,000. Rhumbline Advisers acquired a new position in Cascadian Therapeutics during the 2nd quarter valued at about $143,000. Finally, Bank of America Corp DE boosted its stake in Cascadian Therapeutics by 2,316.5% during the 1st quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 35,975 shares during the period. 80.35% of the stock is owned by institutional investors.
Shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) opened at $4.04 on Tuesday. Cascadian Therapeutics, Inc. has a one year low of $3.18 and a one year high of $6.72.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 target price on shares of Cascadian Therapeutics in a research note on Monday, September 11th. Barclays assumed coverage on shares of Cascadian Therapeutics in a research note on Wednesday, September 6th. They set an “underweight” rating and a $4.00 target price for the company. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Cowen reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.63.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/05/cascadian-therapeutics-inc-casc-shares-bought-by-northern-trust-corp.html.
Cascadian Therapeutics Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
What are top analysts saying about Cascadian Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cascadian Therapeutics Inc. and related companies.